SCHEMBL20893271

SCHEMBL20893271

CCOC(=O)c1cc(O)c(=O)c(OCc2ccccc2)cc1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ PPIA P62937 2/20 0.47
▸ CA12 O43570 2/20 0.45
▸ CA1 P00915 2/20 0.45
▸ CA2 P00918 2/20 0.45
▸ CA7 P43166 2/20 0.45
▸ CA9 Q16790 2/20 0.45
▸ CA14 Q9ULX7 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ NMT1 P30419 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19821457 0.82 MEN1 (0.54) MAOBMEN1HSP90AA1KMT2APPIA
SCHEMBL18209404 0.81 MEN1 (0.50) MAOBMEN1HSP90AA1KMT2APPIA
SCHEMBL24983814 0.80 ALDH1A1 (0.54) KMT2ATDP1HTTMAPTCYP2C9
SCHEMBL23796824 0.80 MEN1 (0.60) MAOBMEN1HSP90AA1KMT2APPIA
SCHEMBL19349238 0.79 HSD17B2 (0.54) KMT2ACA12CA1CA2CA7
SCHEMBL340937 0.77 HTT (0.69) MEN1HSP90AA1KMT2APPIATDP1
SCHEMBL28877494 0.77 MEN1 (0.54) MAOBMEN1HSP90AA1KMT2APPIA
SCHEMBL1561028 0.77 EGFR (0.59) PPIACA12CA1CA2CA7
SCHEMBL18311390 0.77 CA12 (0.53) MAOBKMT2ACA12CA1CA2
SCHEMBL23796432 0.77 MEN1 (0.56) MAOBMEN1HSP90AA1KMT2APPIA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10889556-B2 Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-01-12 — — US disclosed
US-20190106398-A1 COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-04-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106398-A1 COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE POLRMT, RNASE1, POLM MAOB 269/4885MEN1 3312/4885HSP90AA1 1811/4885
US-10889556-B2 Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease POLRMT, RNASE1, POLM MAOB 269/4885MEN1 3312/4885HSP90AA1 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback